Strand Life Sciences to Highlight Clinical Utility Data for StrandAdvantage at 2015 ASCO Annual Meeting

May 14, 2015, 08:00 ET from Strand Life Sciences

AURORA, Colorado, May 14, 2015 /PRNewswire/ --

Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced that data regarding the clinical utility of StrandAdvantage, the company's pan-cancer genomic profiling service, will be featured online at abstracts.asco.org as part of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

The company will also host a presentation entitled "StrandAdvantage: Fast, Actionable & Relevant Treatment Options for Cancer Patients" led by Scott A. Storrer, Strand's global president, and Dr. Preveen Ramamoorthy, the company's global head of diagnostics, at 9:15 a.m. on Saturday, May 30, at an Industry Expert Theater, located in the back of the Oncology Professionals Hall. Visit Strand at booth number 18158 for more information about its products and offerings.

"Our Industry Expert Theater will explain how StrandAdvantage provides oncologists and pathologists with a complete understanding of genomic changes in solid tumors, thus enabling the development of uniquely individualized treatment for cancer patients," Storrer said. "StrandAdvantage is designed for physicians to use as a resource when making first-line therapy decisions."

Strand's online data publications include:

- Analytical Validation of StrandAdvantage Solid Tumor NGS Test 

Abstract #e12539 (publication only)

http://abstracts.asco.org/156/AbstView_156_151243.html

 

- Clinical Utility of Profiling Somatic Alterations in Indian Cancer Patients Using a Multi-Gene Next Generation Sequencing (NGS) Test 

Abstract #e22127 (publication only)

http://abstracts.asco.org/156/AbstView_156_151373.html

 

- Clinical Utility of PI3K/AKT/mTOR Pathway Activation in Breast Cancer: A study in Indian Population 

Abstract #e12542 (publication only)

http://abstracts.asco.org/156/AbstView_156_151124.html

 

- Targeted Sequencing Confirms Clinical Diagnosis of Li-Fraumeni Syndrome 

Abstract #e22052 (publication only)

http://abstracts.asco.org/156/AbstView_156_151430.html

 

StrandAdvantage is designed to accelerate the analysis of therapeutically actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests. StrandAdvantage provides oncologists with clinically actionable results beginning with a report on eight "standard-of-care" genes delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.

About Strand Life Sciences 

Strand Life Sciences is a genomic profiling company that uses next-generation sequencing (NGS) technology aimed at empowering cancer care. Strand's StrandAdvantage pan-cancer panels provide medical oncologists a complete understanding of genomic changes in solid tumors in days, so targeted treatment plans can begin quickly. Strand's comprehensive knowledge base of genomic variants linked to FDA-approved targeted cancer therapies and drugs in open clinical trials provide clinically actionable treatment options, enabling clinicians to develop a truly personalized treatment regimen for cancer patients. For more information, please visit http://www.strandls.com.

Contact:

Doreen Korba
Vice President, Marketing
888-801-9164
doreen@strandls.com

David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
(212) 845-4271
(212) 845-4235
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
 

Editor's Note: StrandAdvantage will be on display at Booth 18158 in the Oncology Professionals Hall at ASCO 2015.

SOURCE Strand Life Sciences